Introduction
A large number of substances have been classified in the World Anti-Doping Agency (WADA) List of Prohibited Substances for anti-doping purposes. This includes various classes, such as anabolic agents (endogenous/exogenous), peptide hormones, beta-2-agonists, hormone and metabolic modulators, diuretics, masking agents, stimulants, narcotics, cannabinoids, glucocorticosteroids, alcohol and b-blockers (1). Pursuing its responsibilities and in accordance with the World Anti-Doping Code, every year WADA publishes two sets of statistics, one reported by the WADA-Accredited Laboratories on their analyses and the other by the Anti-Doping Organizations (ADOs) including testing and results management, after having matched longitudinal studies and Therapeutic Use Exemptions (TUEs) (2) (3) (4) (5) . Currently, these data are reprocessed and registered by the WADA as both Atypical Findings (ATFs; inconclusive findings) and Adverse Analytical Findings (AAFs; positive findings) (3 -5) . The concept of ATF as regards the AAF was introduced in the 2008 International Standard for Laboratories (ISLs) and formalized by the 2009 World Anti-Doping Code (3, 6) .
Right from the beginning, the List of Prohibited Substances has been a yearly revised document. From 2005 till 2011, there were many alterations on the International Standards Prohibited List, e.g., the introduction of methylhexaneamine in 2010 and also on the relevant technical documents, e.g., the modification of the T/E ratio from 6 to 4 in 2004, which was activated in 2005 in the Doping Control Laboratory of Athens (DCLA) (7, 8) . Such alterations went hand in hand with the increasing need for traceable doping substances, possibly near the Minimum Required Performance Level (MRPL), and thus for proper adjustments on instrumentation/methodologies (9) (10) (11) . In terms of the preventive doping control policy, improved methodologies permitted the detection of new designer drugs by screening of their long-term metabolites (12) . New analytical challenges currently propose the use of orbitrap as well as gas chromatographytandem spectrometry (GC-MS-MS) analyzers to enhance sensitivity (13) . Especially for steroid analysis, the triple quadrupole (QqQ) apparatus has been proposed as superior to quadrupole time-of-flight (QTOF) and TOF analyzers, as the latter did not meet the MRPL criteria in all target compounds (14) . Besides, the adding effect of retrospective detection via TOF, QTOF or orbitrap mass analyzers, holding the advantage of acquiring full mass spectra and revealing athletes misuse, has been pointed out (15) . Finally, there has been common need among the WADA-Accredited Laboratories to optimize their methods for multiresidue analyses, in order also to achieve better laboratory economy, i.e., in the capital costs, reporting times.
Nowadays, 33 WADA-Accredited Laboratories perform the analyses of the athletes' samples for doping control in sports internationally. Among these is the DCLA, which was founded in 1986 (located in the outskirts of the Olympic Athletic Center of Athens) and has performed so far three major events relative to the doping control: the sixth World Championships in athletics in 1997 (16) , the 28th Olympic Games in 2004 (17, 18) and the 17th Mediterranean Games in 2013. Since 2000, the DCLA has undergone the standard accreditation procedures: (i) the ISO/ Hellenic Accreditation Body (ESYD) 17025 accreditation by the ESYD, (ii) the External Quality Assessment Scheme [EQAS; including yearly the three proficiency-testing, the double-blind tests and educational proficiency test (PT) samples] by the WADA, (iii) the proficiency test by the Association of Official Racing Chemists (AORC) (16, 17) and finally, (v) the educational PT samples by the World Association of Anti-Doping Scientists (WAADS). More specifically, the WADA EQAS comprises a system ensuring uniformity among the Accredited Laboratories and simultaneously evaluating their performance. Besides, a severe penalty system is imposed by the WADA via a point system on certain discrepancies of the Accredited Laboratories from the ISL, which may lead to either temporary or permanent suspense, i.e., temporary withdrawal of Accreditation or entire revocation.
As the other Accredited Laboratories, DCLA also has had to conform to the co-current WADA demands. This has been either in the direction of different data management (as AAFs versus ATFs) or the employment of new methods or instrumentation. For instance, as athletes seemed to make use of small doses of substances (microdosing) lately (19) , a higher sensitivity technique like liquid chromatography/quadrupole/time-of-flight mass spectrometry (LC-Q-TOFMS) had to be introduced, so that detection limits can lower down to MRPL and also detection may be permitted for longer times up to athletes clearance (12, 20) . Even more, for better management of the laboratory resources and the human labor, a unification sample method had to be applied (21) . Along these lines, the DCLA analytical data from 2005 to 2011 are reviewed below, based on the latest updated List of Prohibited Substances and the relevant requirements of WADA. In this study, it is attempted to identify the factors that imposed alterations during this period in the data management, the instrumentation and the methods used relative to preparation and laboratory economy, so that DCLA results are always approved by the authorities.
Methods/apparatus
Data were collected from the in-house database that included all documented positive samples and from the WADA yearly Laboratory Statistics. The compiled data of this laboratory from 2005 to 2011, in a total of 30,000 athlete urine samples, are presented below. Athlete urine samples were collected according to the International Standards and Testing (IST) and analyzed according to the ISL and the Code of Ethics (Declaration of Helsinki). Detection and measurement of the prohibited substances was carried out using the Standard Accredited Methods employing GC-MS, GC-high-resolution mass spectrometry (GC-HRMS), GC-combustion/isotope ratio mass spectrometry (GC-C-IRMS), LC-mass spectrometry (LC-MS) and LC-Q-TOFMS instrumentation (18) . The analysis of the trimethyl silylated-derivatized target substances, such as anabolic steroids, was performed on an Agilent 6890N GC system (Agilent Technologies, Santa Clara, CA, USA) coupled with an Agilent 5973 inert mass selective detector and MS source with a quadrupole. Chromatographic separation was implemented with a bonded and cross-linked 5% diphenyl, 95% dimethyl siloxan capillary column (17 Â 0.2 mm i.d., 0.33 mm film thickness, HP ULTRA 1) (22) . The GC-HRMS analysis was performed in a Waters Micromass AutoSpec Ultima (Manchester, UK) coupled with an Agilent Ultra 1GC column (12-m length, 0.2 mm i.d., 0.33 mm film thickness). Sample clean-up was performed on a high-performance liquid chromatograph HP 1090 (Agilent Technologies, Germany) with a Merck analytical column (LiChrospher 100RP, 125 Â 4 mm i.d., 5 mm particle size) and an automatic injection system. Carbon isotope measurements were performed on an Isoprime GC-C-IRMS instrument (Isoprime Ltd., Cheadle Hulme, UK) coupled with a 6890N Gas Chromatograph (Agilent Technologies, USA) and a combustion system (22, 23) . A combined doping control screening method has been applied since 2010 for the routine combined analysis of narcotics, diuretics, b-blockers, anabolic steroids, etc. in human urine LC-Q-TOFMS (20, 21 ). An Agilent 1200 series (Agilent Technologies, USA) Rapid Resolution LC system was used for the chromatographic separation. The system consisted of a vacuum degasser, a two-piston binary pump, an autosampler and a column oven. Chromatographic separation is performed at 358C using a Zorbax Eclipse Plus C18 column (100 Â 2.1, 1.8 mm particle size; Agilent Technologies). The mass spectrometer is an orthogonal acceleration quadrupole time-offlight mass spectrometer (6520 Accurate-Mass LC-Q-TOFMS; Agilent Technologies, USA) equipped with an orthogonal electrospray ionization source, a temperature-stabilized analogue-to-digital converter (ADC) operated at 2 GHz (extended dynamic range mode) and a multichannel plate operated at 700 V. The % occurrences for T/E ratios of .4 account for the 58% of the anabolic agents reported in this search (Table I) . While the technical document on the T/E ratio changed from T/E .6 to .4 in 2004 (in DCLA, this was applied from 2005 onwards), in the data of 2005-2011 it can be seen that in 67% of the occurrences the mean T/E ratios varied from 4.4 + 0.2 to 5.8 + 0.2 (i.e., data between 4 and 6.04, 94 measurements) and in the rest 33% from 6.3 + 0.2 to 22.5 + 2.9 (i.e., data between 6.1 and 26.4, 39 measurements), these two ranges varying statistically according to the two-sided t-test (jtj ¼ 4.89 above the t c ¼ 2.03, P , 0.05; Figure 2a Among other anabolic substances, there were 23 positive cases for 19-norandrosterone (Table I ). According to Table I , substances like stanozolol, clenbuterol, oxandrolone, methandienone and 19-norandrosterone were found in some strength sports such as in bodybuilding and weight lifting.
Results

In
The mean THCCOOH concentration values of .15 ng/mL (threshold value), in the examined athlete samples, varied from 19.1 + 0.6 to 56.9 + 6.2 ng/mL (Figure 3a) with maximum % THCCOOH occurrence in values between 30 and 63.1 ng/mL (Figure 3b ). In the attempt to achieve lower limits of detection (LOD) at the lowest possible cost and time effectiveness, a new method was developed, employing improved the LC-Q-TOFMS apparatus (20) . This method traceability, as for over 1000 re-examined stored samples of January -June 2009 initially negative, there were 11 samples with methylhexaneamine, following reporting to WADA (LOD of the method ,250 ng/mL). Overall 21 cases found for methylhexaneamine account for the 4.9% of the total analytical findings in DCLA for the period of 2005-2011 (Table I ).
The LC-Q-TOFMS method was extended in 2010 in order to screen substances from different categories (such as anabolic agents, b-blockers, stimulants, narcotics and diuretics) (20, 21) for routine screening, this effecting on cut-down of preparative costs and reporting times, with the preparative time being decreased, i.e., from four preparation procedures in to a single one, plus the lowering of capital costs due to detection of a complex of substances in one instrument (i.e., LC-Q-TOFMS). It is though common practice for safety reasons that still different methodologies are used in parallel such as GC-MS and GC-HRMS in order to monitor same substance classes.
In fact during these years, the prohibited substances methylhexaneamine and amphetamine and other anabolic substances such as clenbuterol, stanozolol, methenolone, etc. were detected below the MRPL via different instrumentation, such as LC-Q-TOFMS, GC-HRMS and GC-MS (Table II) . The % of samples detected below the MRPL was increased to 22% in 2011. Also, the % of B samples relative to total AAFs demanded by the authorities from 2005 to 2011 varied from 4.9 to 21.3% (Table II) . 
Discussion
The term ATF-first referred in IST and in the 2009 World Anti-Doping Code (6), while applied by the WADA on statistical data of 2008 (3)-led to a more detailed distribution of positive samples from WADA laboratories, such that almost half of athlete samples ended up as inconclusive samples (ATFs) with a need for further investigation (mainly with IRMS) and the other half as AAFs (Figure 1 ). Similar trends were seen in the data of Doping Control Laboratory of DCLA, as according to the statistical evaluation the total findings (% AAFS plus ATFs) were statistically similar (two-paired t-test at the 95% confidence level) (Figure 1) . Also, % ATFs were statistically similar according to the two tailed t-test. Additionally, the general trends of analytical findings are in line with previous investigation (25) .
According to the WADA guidelines, the T/E threshold value has changed from 6 to 4 from 2004 with the exception of DCLA, which employed this measure on 2005, after ending the doping control analysis of the Olympics of 2004 (7). In DCLA, the % occurrences for T/E ratios .4 (threshold value) were predominant relative to the rest of anabolic substances (Table I ) and gave maximum in 2008 (Figure 2b) . Besides, the examination of mean testosterone/epitestosterone ratio (T/E) over 4 from 2005 to 2011 suggests that, in the majority of % occurrences with a T/E of .4 ( 67%), the mean T/E varied between 4.4 + 0.2 and 5.8 + 0.2 (range values for T/E from 4 to 6.04) (Figure 2a) . However, it has been suggested elsewhere that the T/E ratios from 4 to 6 do not always imply exogenous testosterone administration (2), according to the findings of GC-C-IRMS analysis (only 0.4% of GC-C-IRMS analyzed samples were positive), thus letting such cases as ATFs (2) . Indeed, in this laboratory, 90% of T/E .4 were characterized as ATFs from 2008 to 2011, the majority of T/E values lying in the range 4 -6.04.
The % occurrences for cannabis, secondly more abused substance according to our findings, with 43 positive cases (with a threshold value of THCCOOH at 15 ng/mL), did constantly vary from 2005 to 2011 (Figure 3b) , with maximum occurrence in basketball athletes (Table I) . However, the increased number of Figure 3 . (a) Percent THCCOOH occurrences .15 ng/mL per total number of THCCOOH versus the mean THCCOOH concentration (+SD), where the mean THCCOOH were taken from batches of close data, in order to investigate the range 19.1 + 0.6 -23.9 + 4.1 (values between 18.5-threshold 15 ng/mL plus uncertainty-and 28 ng/mL) and from 30 to 56.9 + 6.2, i.e., 30-63.1 ng/mL (the two ranges were statistically different according to two-sided t-test, P , 0.05) and (b) % THCCOOH occurrences .15 ng/mL (threshold value) per examined sample number per year (data of DCLA from 2005 to 2011).
samples examined from this sport may have biased this finding. On the other hand, it was rather difficult to impose further statistical analysis due to the small number of positives per sport of positive samples (43 in total from various sports). The consumption of tetrahydrocannabinol metabolite in the 65% of samples leveled from 30 to 63.1 ng/mL, a statistically distinct range from 18.5 to 28 ng/mL. The level of THCCOOH consumption found in athletes these previous years showed a real tendency for higher concentration than 30 ng/mL, such that a 15 ng/mL previous threshold value may have been rather low. This may have led to the latest decision of increasing the threshold to 150 ng/ mL from 1 May 2013 (26) . On the other hand, such a decision always allows for higher consumption of the substance during the official games.
In the attempt to achieve lower LODs, to cut down on costs and to improve time effectiveness, a new method was developed using the LC-Q-TOFMS analytical technique (20) . With an MS technology of high-resolution and full-scan acquisition mode coupled with GC or LC systems, it is possible to retrospectively detect designer drugs or their metabolites by simple reprocessing the already acquired LC-MS or GC-MS data (12) . This method permitted the screening of 11 of 21 cases with methylhexaneamine by reprocessing a lot of 1000 samples; three of those were detected below the MRPL (Table II) (20) . The methylhexaneamine was a substance introduced in 2010 by the WADA Prohibited List (8) . The introduction of LC-Q-TOFMS, indeed, added up to the issue of preventive anti-doping. The idea started in 2004 in the Athens Olympic Games, when WADA included in its Anti-Doping Code storage athlete samples for 8 years a policy duplicated by the IOC (18, 27) . It is currently under discussion to elevate this period of sample re-examination from 8 up to 14 years. Indeed, 8 years later from 2004, sample evaluation led to further tracing of positive cases, a fact that may happen also in following Olympiads. Indeed, as new designer drugs may illegally enter the markets and athletes use them, such substances or their long-term metabolites may be discovered in second time, by retrospective analysis of their chromatographic data, thus to result as positive samples (AAFs). This in effect adds up to the laboratory economy by elimination of repeated sample preparation (12) .
The detection of substances below the MRPL, in this laboratory, was seen up to 22.1% in 2011 (Table II) using various methodologies (GC-MS, GC-HRMS and LC-Q-TOFMS). This suggests the late use of complex substances in small doses (microdosing), the method of choice among athletes (19) . Indeed, there is an increasing need for traceable doping substances at the lowest possible LODs, especially lately where MRPL values have been reduced (10, 11) . Therefore, further adjustments have been required by the DCLA. Currently, the MRPL values are at maximum 5 ng/mL for most anabolic steroids and 2 ng/mL for some others (11) . From Table II , it can be deduced that GC-HRMS provided the detection of anabolic steroids below the MRPL. In some substances, the LC-MS or LC-Q-TOFMS provided detection below the half of the MRPL (see Table II ). This can be of great value especially during athletes' competition games. It has been stated before that the fact that there have been so many positives in 2004 Athens Olympic Games was also due to the high sensitivity of the latest equipment provided (e.g., HRMS, LC-MS), so that even if athletes stayed clear for 2 -4 days, they could still be detected with low levels of substances (28) .
In addition, the need for better laboratory economy (capital costs, reporting times etc.) and lower MRPL values led, along with the other WADA-Accredited Laboratories, to method fusion (29) . The LC-Q-TOFMS was used for this purpose, which minimized thrice the schedule of sample preparation and chromatographical data processing, thus resulting in a 10-day reporting time to the authorities. However, substances with variant traceability were crosschecked by two different methodologies, such as GC-HRMS and LC-Q-TOFMS.
The future potential of decreasing even more the LOD and MRPL on the prohibited substances still remains a challenge for anti-doping laboratories (30, 31) . Therefore, the selection and design of unified analytical protocols is crucial, starting from sample preparation to the advanced instrumental analysis, in order to enhance the possibility for successful detection of newly emerging chemical structures of various classes of substances, even having different physical and chemical properties. Besides, in the introduction of new types of mass analyzers, such as the linear ion trap or the orbital trap, the tendency is to increase both resolution and mass accuracy. Last generation TOFs or orbital trap instruments offer new capabilities for separating very complex mixtures containing isobaric compounds. Continuous progress on electronic and computing devices also permits to increase the scanning speed of the corresponding MS instruments, which direct consequences on multiresidue monitoring and coupling with fast, high-resolution or two-dimensional chromatography. GC-HRMS, gas chromatography-high-resolution mass spectrometry; GC-MS, gas chromatographymass spectrometry; LC-MS, liquid chromatography-mass spectrometry; LC-Q-TOFMS, liquid chromatography/quadrupole/time-of-flight mass spectrometry.
The relative low number of B-samples requested by the authorities-21.3% the highest in 2006-generally suggests a compromise with A-sample results, as confirmed by this Laboratory. During the Olympics in 2004, there was also a low number of B-samples requested by the athletes suggesting confidence on the DCLA results, since during the period of games athletes may have fairly easy access to B-samples upon their request. It has been stated, however, that A-and B-samples are duplicates handled with the same way by a different analyst, such that theoretically there should be no other result (32) . 
Conclusions
